Literature DB >> 10547605

Pathological features of glycogen storage disease type II highlighted in the knockout mouse model.

A G Bijvoet1, H Van Hirtum, M Vermey, D Van Leenen, A T Van Der Ploeg, W J Mooi, A J Reuser.   

Abstract

Glycogen storage disease type II (GSDII; Pompe's disease) is an autosomal recessive disease caused by lysosomal alpha-glucosidase deficiency. Skeletal muscle weakness is the most conspicuous clinical symptom of patients suffering from GSDII and skeletal muscle also is prominently involved in the knockout mouse model of this disease. Thus far, however, little detailed information has been published on the pathological changes in other mouse tissues. This paper aims to provide these data and gives a record of the clinical course of the mouse model over a 2-year period. Four-month-old affected mice perform worse in a running wheel than their unaffected littermates, but do not yet display other clear signs of disease. The lysosomal glycogen storage, already evident at birth, becomes more severe in time, leading to muscle wasting by 9-10 months of age and then limb girdle weakness and kyphosis. The disease does not markedly shorten the animal's life span despite the serious tissue pathology, which is not limited to heart and skeletal muscle, but is also seen in the smooth muscle of blood vessels and of the respiratory, digestive, and urogenital tracts. In addition, the mice have lysosomal glycogen storage in the liver, kidney, spleen, and salivary gland; in Schwann cells of the peripheral nerves, and in a subset of neurons in the central nervous system. By pathological criteria, the knockout mouse model parallels the human infantile form of GSDII and is attractive for studying the possible reversal of tissue pathology and symptomatology under different therapeutic regimes. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10547605     DOI: 10.1002/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

1.  A modified PAS stain combined with immunofluorescence for quantitative analyses of glycogen in muscle sections.

Authors:  Gert Schaart; Reinout P Hesselink; Hans A Keizer; Gerrit van Kranenburg; Maarten R Drost; Matthijs K C Hesselink
Journal:  Histochem Cell Biol       Date:  2004-08-03       Impact factor: 4.304

2.  Urge incontinence and gastrointestinal symptoms in adult patients with pompe disease: a cross-sectional survey.

Authors:  Nesrin Karabul; Anika Skudlarek; Janine Berndt; Cornelia Kornblum; Rudolf A Kley; Stephan Wenninger; Nikolaus Tiling; Eugen Mengel; Ursula Plöckinger; Matthias Vorgerd; Marcus Deschauer; Benedikt Schoser; Frank Hanisch
Journal:  JIMD Rep       Date:  2014-08-26

Review 3.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

Review 4.  The natural course of non-classic Pompe's disease; a review of 225 published cases.

Authors:  Léon P F Winkel; Marloes L C Hagemans; Pieter A van Doorn; M Christa B Loonen; Wim J C Hop; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2005-08       Impact factor: 4.849

5.  Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease.

Authors:  Sabrina Sacconi; Jonathan D Bocquet; Stéphane Chanalet; Véronique Tanant; Leonardo Salviati; Claude Desnuelle
Journal:  J Neurol       Date:  2010-06-18       Impact factor: 4.849

6.  Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease.

Authors:  Nina Raben; Victoria Hill; Lauren Shea; Shoichi Takikita; Rebecca Baum; Noboru Mizushima; Evelyn Ralston; Paul Plotz
Journal:  Hum Mol Genet       Date:  2008-09-09       Impact factor: 6.150

7.  Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice.

Authors:  Richard L Sidman; Tatyana Taksir; Jonathan Fidler; Michael Zhao; James C Dodge; Marco A Passini; Nina Raben; Beth L Thurberg; Seng H Cheng; Lamya S Shihabuddin
Journal:  J Neuropathol Exp Neurol       Date:  2008-08       Impact factor: 3.685

Review 8.  Non-muscle involvement in late-onset glycogenosis II.

Authors:  Massimiliano Filosto; Alice Todeschini; Maria Sofia Cotelli; Valentina Vielmi; Fabrizio Rinaldi; Silvia Rota; Mauro Scarpelli; Alessandro Padovani
Journal:  Acta Myol       Date:  2013-10

9.  Glycogenosome accumulation in the arrector pili muscle in Pompe disease.

Authors:  Istvan Katona; Joachim Weis; Frank Hanisch
Journal:  Orphanet J Rare Dis       Date:  2014-02-05       Impact factor: 4.123

10.  Late-onset Pompe disease with complicated intracranial aneurysm: a Chinese case report.

Authors:  Bin Zhang; Yuying Zhao; Junling Liu; Ling Li; Jingli Shan; Dandan Zhao; Chuanzhu Yan
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-29       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.